CeNeRx BioPharma, Inc. Completes $4.85 Million Financing
12/9/2011 7:13:16 AM
More...
|
CeNeRx BioPharma, Inc. Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study
2/9/2011 7:53:59 AM
More...
|
CeNeRx BioPharma, Inc. Initiates Phase II Trial of TriRima(TM) as Monotherapy in Treatment Resistant Depression
1/6/2011 6:39:35 AM
More...
|
CeNeRx BioPharma, Inc.'s Novel Antidepressant TriRima(TM) Demonstrates Key Safety Benefit in Pivotal Safety Study
11/2/2010 10:55:59 AM
More...
|
CeNeRx BioPharma, Inc. Completes $13 Million Series C Financing
8/13/2010 7:02:04 AM
More...
|
New Clinical Study Shows Anxiolytic Potential of CeNeRx BioPharma, Inc.'s Novel Mechanism HPA Axis Modulator Compounds
1/12/2010 2:31:07 PM
More...
|
Publication in Neuropsychopharmacology Confirms CeNeRx BioPharma, Inc.'s Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
12/7/2009 2:12:13 PM
More...
|
CeNeRx BioPharma, Inc. Completes $9 Million Financing
6/16/2009 7:24:03 AM
More...
|
CeNeRx BioPharma, Inc. Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
6/16/2009 7:22:51 AM
More...
|
CeNeRx BioPharma, Inc. Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
4/1/2009 9:07:47 AM
More...
|
|